VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the pricing of its upsized underwritten public offering of 10,526,317 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 877,194 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $57.00 per common share and the pre-funded warrants are being offered at a price of $56.9999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $650.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,710,526 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about March 12, 2026, subject to the satisfaction of customary closing conditions.
